Literature DB >> 3105570

Cytotoxic effects of tumour necrosis factor and gamma-interferon on acute myeloid leukaemia blasts.

G Price, M K Brenner, H G Prentice, A V Hoffbrand, A C Newland.   

Abstract

We have studied the cytotoxic effects of recombinant tumour necrosis factor and recombinant gamma interferon on primary cultures of leukaemia cells. The agents were added alone or in a combination to cells from 17 patients. Eleven had acute myeloblastic leukaemia (6 at presentation, 5 at relapse), 4 had acute lymphoblastic leukaemia, one had hairy cell leukaemia, and 2 had chronic myeloid leukaemia--one of whom was in myeloid blast transformation. Cells from patients with lymphoid malignancies or from the patient with chronic phase CML were not affected by either agent in any dose combination. In contrast, reduction of viability of myeloid blasts was weakly accelerated by TNF and gamma-interferon individually. Combination of the agents invariably produced enhanced killing and additive or synergistic effects were seen when 20-500 IU ml-1 of each cytokine was present. This sensitivity was also shown by blast cells from 5 patients with relapsed AML. We therefore suggest that trials of such combination therapy may be indicated in drug resistant or relapsed AML.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3105570      PMCID: PMC2001744          DOI: 10.1038/bjc.1987.55

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Lymphocyte in vitro cytotoxicity: mechanisms of immune and non-immune small lymphocyte mediated target L cell destruction.

Authors:  G A Granger; W P Kolb
Journal:  J Immunol       Date:  1968-07       Impact factor: 5.422

2.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

3.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.

Authors:  D Pennica; G E Nedwin; J S Hayflick; P H Seeburg; R Derynck; M A Palladino; W J Kohr; B B Aggarwal; D V Goeddel
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

4.  Purification and physico-chemical characterization of rabbit tumor necrosis factor.

Authors:  M R Ruff; G E Gifford
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

5.  Demonstration of membrane receptors for human natural and recombinant 125I-labeled tumor necrosis factor on HeLa cell clones and their role in tumor cell sensitivity.

Authors:  V Lehmann; W Dröge
Journal:  Eur J Biochem       Date:  1986-07-01

6.  Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.

Authors:  S A Rosenberg; J J Mulé
Journal:  Surgery       Date:  1985-09       Impact factor: 3.982

7.  Treatment of hairy cell leukemia with recombinant alpha 2 interferon.

Authors:  M J Ratain; H M Golomb; J W Vardiman; E E Vokes; R H Jacobs; K Daly
Journal:  Blood       Date:  1985-03       Impact factor: 22.113

8.  Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity.

Authors:  P W Gray; B B Aggarwal; C V Benton; T S Bringman; W J Henzel; J A Jarrett; D W Leung; B Moffat; P Ng; L P Svedersky
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

9.  Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo.

Authors:  B A Beutler; I W Milsark; A Cerami
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

10.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.

Authors:  B Beutler; D Greenwald; J D Hulmes; M Chang; Y C Pan; J Mathison; R Ulevitch; A Cerami
Journal:  Nature       Date:  1985 Aug 8-14       Impact factor: 49.962

View more
  6 in total

1.  Effect of cell isolation methods and drug concentration on the use of the Differential Staining Cytotoxicity (DiSC) assay with solid tumours.

Authors:  A G Bosanquet; S Forskitt
Journal:  Cytotechnology       Date:  1989-08       Impact factor: 2.058

Review 2.  Tumour necrosis factor: a cytokine with multiple biological activities.

Authors:  G Semenzato
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

3.  Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study.

Authors:  S H Lim; A C Newland; S Kelsey; A Bell; E Offerman; C Rist; D Gozzard; D Bareford; M P Smith; A H Goldstone
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 4.  Role of interleukin-2 in human hematological malignancies.

Authors:  A Toren; A Ackerstein; S Slavin; A Nagler
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

5.  IL-4 acts as a homeostatic regulator of IL-2-induced TNF and IFN-gamma.

Authors:  C Bello-Fernandez; P Oblakowski; A Meager; A S Duncombe; D M Rill; A V Hoffbrand; M K Brenner
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

6.  Antiseptic effect of sea cucumber (Holothuria atra) against multi-organ failure induced by sepsis: Molecular and histopathological study.

Authors:  Dalia Y Saad; Ahmed A Baiomy; Ahmed A Mansour
Journal:  Exp Ther Med       Date:  2016-05-10       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.